- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00255970
Regenafil Versus Demineralized Freeze Dried Bone Allograft (DFDBA) for Periodontal Defects
Regenerative Therapy for Vertical Defects Comparing Demineralized Freeze Dried Bone Allograft (DFDBA) and Regenafil
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To compare the regenerative effects of a demineralized freeze dried bone allograft (DFDBA) particulate in a biologic thermoplastic carrier (Regenafil) to the standard of care. To compare the regenerative effects of a demineralized freeze dried bone allograft (DFDBA) particulate in the treatment of intraosseous vertical defects following six months of healing. This was accomplished by evaluating clinical parameters including probing depth, attachment level and bleeding upon probing, using attachment level as the primary outcome variable.
Treatment of the vertical osseous defect is a challenging problem in periodontics. There are many treatment options including:
- open flap debridement;
- osseous graft alone;
- membrane alone;
- or membrane plus an osseous graft.
Choice of treatment may depend on the defect depth and configuration. A shallow, narrow 3 wall defect may respond well to open flap debridement while a deep 2 wall defect may need regenerative therapy such as an osseous graft, a membrane or combined membrane and graft treatment. Studies of vertical defect therapy with defects about 4 mm or greater show that similar percent defect fill results are obtained with regenerative therapies. Open flap debridement produces substantially less percent defect fill.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University School of Dentistry
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville School of Dentistry
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide written informed consent prior to their participation.
- Be an adult age 18 and older.
- Have at least a 4 mm open vertical osseous defect depth on one tooth, visible on a radiograph and with a probing depth ≥ 5 mm.
- Have osseous defects that are either wide 3-wall, or combination defects.
Exclusion Criteria:
- Have debilitating systemic diseases, or diseases that affect the periodontium.
Have a known allergy to any of the materials that will be used in the study:
- non-steroidal anti-inflammatory drugs (NSAIDs)
- chlorhexidine digluconate
- doxycycline
- gelatin
- Need prophylactic antibiotics.
- Have a vertical osseous defect that is related to a furcation area.
- Smoke more than 1 pack per day.
- Have endodontically treated teeth or endodontic lesions at study sites.
- Have 1-wall defects.
- Have poor oral hygiene.
- Have anterior fillings (Note: if a subject presents with anterior fillings, it will be at the discretion of the principal investigator as to whether they should be accepted into the study.)
- Be pregnant as evidenced by a positive urine pregnancy test taken at both the screening and baseline visits.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Regenafil graft
Regenafil
|
Demineralized Freeze Dried Bone in a porcine gel carrier
Other Names:
|
|
ACTIVE_COMPARATOR: DFDBA
Demineralized Freeze Dried Bone Allograft
|
Demineralized Freeze Dried Bone in a porcine gel carrier
Other Names:
Demineralized Freeze Dried Allograft bone
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Probing Depth
Time Frame: baseline and then at 6 months
|
This is the distance, measured in millimeters (mm) from the gingival margin to the maximal penetration of the probe tip.
The measures were made at baseline and then at 6 months after treatment.
|
baseline and then at 6 months
|
|
Clinical Attachment Level
Time Frame: 6 months
|
The amount of space between attached periodontal tissues and a fixed point, usually the cementoenamel junction.
A measurement used to assess the stability of attachment as part of a periodontal maintenance program.
|
6 months
|
|
Recession
Time Frame: 6 months
|
CEJ to gingival margin (GM).
GM coronal to the CEJ were scored as a negative number.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gingival Index
Time Frame: 6 months
|
Scores: 0 Normal gingiva
|
6 months
|
|
Plaque Index
Time Frame: 6 months
|
0- No plaque
|
6 months
|
|
Bleeding on Probing
Time Frame: 6 months
|
The variable measured the presence of bleeding when the osseus defect was probed. The presence and character of gingival bleeding will be determined by gently probing to the base of the pockets. 0 - No bleeding. 1 - Bleeding when probing. |
6 months
|
|
Mobility Index
Time Frame: 6 months
|
Tooth mobility was recorded using Miller's Index:
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Steven Blanchard, DDS, Indiana University
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RegenF052005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.